RetinUp Podcast
oleh RetinUp Podcast, LLC
Breaking News: Imvionix Acquires Beovu in the US and Canada
Tentang podcast ini
RetinUp is a podcast exploring the latest in retina science and ophthalmology. Hosted by John Kitchens, MD, and Scott Krzywonos, each episode features expert insights, research breakthroughs, and practical discussions designed for ophthalmologists, retina specialists, and vision science researchers.
Episode
20 episode terbaru dari 40
- Breaking News: Imvionix Acquires Beovu in the US and Canada · 9 mnt · Episode 39Imvionix has acquired the exclusive US and Canadian commercial rights to Beovu (brolucizumab) from Novartis. The deal is the first strategic transaction for the new company, led…
- Business of Retina After the Midterms with Tom Stone, MD | Ehsan Rahimy, MD, on the PRIMA Implant · 44 mnt · Episode 38Recorded the after the 2026 midterms, John Kitchens, MD, and Scott Krzywonos ask Thomas Stone, MD, what a shift in Congress could mean for retina practices: drug pricing…
- Big Pharma’s Retina Bets | Don D’Amico, MD, on BRUNELLO | RetinUp Turns One · 43 mnt · Episode 37RetinUp turns one year old. Before the birthday reflections, John Kitchens, MD, and Scott Krzywonos take stock of what the past eighteen months of retina acquisitions actually…
- Breaking News: Alcon Acquires Neurotech · 12 mnt · Episode 36Two pieces of news today, October 21, 2026. Alcon announced the acquisition of Neurotech Pharmaceuticals for $550 million upfront, with additional milestone payments possible…
- Breaking News: LUCIA Misses in Wet AMD — EyePoint Shifts to DME · 8 mnt · Episode 35Breaking news: EyePoint Pharmaceuticals announced this morning that LUCIA, the second pivotal Phase 3 trial of Duravyu (vorolanib, EYP-1901) for wet AMD, did not achieve the…
- AAO 2026 Recap + Vitrectomy for Floaters with Christina Weng, MD, MBA · 42 mnt · Episode 34John Kitchens, MD, and Scott Krzywonos recap the American Academy of Ophthalmology 2026 Annual Meeting in New Orleans — a meeting that delivered on science even as a hurricane…
- The 2026 Data Recap — What to Watch at AAO Next Week · 22 mnt · Episode 33John Kitchens, MD, and Scott Krzywonos take stock of the biggest retina data readouts of 2026 — from a superiority study from Ocular Therapeutix to a Kodiak comeback and a gene…
- Breaking News: Kodiak's DAYBREAK Hits — Zenkuda and Tabirafusp-ted Both Positive · 8 mnt · Episode 32Breaking news: Kodiak Sciences announced this morning that both Zenkuda (tarcocimab tedromer) and tabirafusp-ted (KSI-501, tabirafusp alfa tedromer) met their primary endpoints…
- Breaking News: Merck's Remigromig Hits Primary Endpoint in BRUNELLO for DME [Corrected] · 13 mnt · Episode 31Breaking news: Merck announced this morning that remigromig (MK-3000), its investigational tetravalent tri-specific Wnt pathway agonist, met the primary endpoint of the Phase…
- Breaking News: Beacon's Gene Therapy Laru-zova Hits Primary Endpoint in VISTA for XLRP · 11 mnt · Episode 30Breaking news: Beacon Therapeutics announced positive topline data from the VISTA pivotal trial of laru-zova (laruparetigene zovaparvovec) for X-linked retinitis pigmentosa…
- AAO 2026 Preview | Retina Subspecialty Day & the Talks Worth Showing Up For · 36 mnt · Episode 29John Kitchens, MD, and Scott Krzywonos break down the AAO 2026 annual meeting in New Orleans (October 9–12) — whether it still matters, what to catch at Subspecialty Day, and…
- Pipeline Check-In | Plus Carl Danzig, MD, on His Mid-Career Practice Switch · 38 mnt · Episode 28John Kitchens, MD, and Scott Krzywonos take stock of the three biggest retina news stories of 2026 — the SOL-1 superiority data for Axpaxli (Ocular Therapeutix), the FDA approval…
- Jay Duker, MD, on LUGANO and What Comes Next for Duravyu and EyePoint | Plus, Miles Harper on Successful and Failed OR Innovations · 41 mnt · Episode 27Jay S. Duker, MD, President & CEO of EyePoint Pharmaceuticals, joins John and Scott to parse the LUGANO Phase 3 topline data — just three days after release. He walks through…
- Breaking News: EyePoint's Phase 3 Topline Data Release · 9 mnt · Episode 26Breaking news: EyePoint Pharmaceuticals announced LUGANO Phase 3 topline data this morning. Duravyu, an investigational sustained-release TKI for wet AMD, did not meet its…
- Oncology's Biosimilar Lessons for Retina | Plus, Moving to a New OR · 29 mnt · Episode 25The companion piece to RetinUp’s previous episode on biosimilars is here, featuring an oncologist who has lived through biosimilar disruption for the past decade. Stephen "Fred"…
- Outlook CEO Bob Jahr on the Lytenava Launch | Plus, Miles Harper on Being Connective Tissue for Industry Innovation · 22 mnt · Episode 24Bob Jahr, President & CEO of Outlook Therapeutics, joins John and Scott for one of his first interviews since the Lytenava (bevacizumab-vikg) FDA approval on July 24, 2026. He…
- Breaking News: FDA Approves Lytenava for Wet AMD · 7 mnt · Episode 23Breaking news: the US Food and Drug Administration approved Lytenava (bevacizumab-vikg, Outlook Therapeutics) on July 24, 2026 — making it the first and only FDA-approved…
- Devon Ghodasra, MD, on Biosimilars in Practice | Plus Vas Sadda, MD, on Ultra-Widefield Imaging for a Peripheral Detachment · 31 mnt · Episode 22Show Notes: Guests: Devon Ghodasra, MD – Partner, Southeastern Retina Associates, Chattanooga, Tennessee Vas Sadda, MD – Director, Artificial Intelligence & Imaging Research…
- Jorge Fortun, MD, on Patient Communication, Palm Beach Practice, & ASRS Preview · 24 mnt · Episode 21Jorge Fortun, MD, of Bascom Palmer Eye Institute joins John Kitchens, MD, and Scott Krzywonos for a wide-ranging conversation on the art of retina practice, from the unique…
- Hunter Cherwek, MD, on Orbis International | Plus Frank Brodie, MD, on LensOne & the GOLDEN GATE Trial · 36 mnt · Episode 20Guests: Hunter Cherwek, MD – Vice President, Clinical Services & Technologies, Orbis International Frank Brodie, MD, MBA – Assistant Professor of Ophthalmology, UCSF; Co-Founder…








